Skip to content
thestock.space

Emcure Pharmaceuticals (EMCURE) had a P/E of 38.4× on 6 Nov 2026, above the industry P/E of 28.7×. Sales and net profit grew 15% and 20% a year over 3 years; its ROCE of 25% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.33× equity, and its dividend yield is 0.2%. It is a mid-cap company with a market cap of ₹41,979 Cr, ranked 16th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 69% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹2,224.20
Day high
₹2,253.20
Day low
₹2,181.10
Prev. close
₹2,245.00
Volume
2.3 L

Health check

4 good · 1 fair · 1 to check
  • ReturnsAhead

    +69.5% over a year, better than 6 of 7 peers.

  • Price tagPricier

    P/E 38.4 vs industry 28.7.

  • GrowthStrong

    Sales +15.4%, profit +20.2% a year over 3 years.

  • ProfitabilityStrong

    ROCE 24.7% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.33× equity, interest covered 11.4×, Piotroski 5 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Mid cap

₹41,979 Cr, #16 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹10,234 Cr · profit ₹1,093 Cr
Market cap
₹41,979 Cr
Mid cap
P/E
38.4
Industry 28.7
Price to book
7.86
Peers 4.99
Dividend yield
0.16%
ROE
21.4%
Peers 14.7%
ROCE
24.7%
Peers 17.9%
Debt to equity
0.33
Debt ₹1,757 Cr
EPS (TTM)
₹57.63
Face value ₹10
OPM (TTM)
19.8%
Net margin 10.7%
Sales growth
+24.3%
Latest quarter vs a year ago
Profit growth
+33.7%
Latest quarter vs a year ago
Price to sales
4.10
EV/EBITDA 22.2

Strengths and risks

Strengths

  • Return on equity of 21.4%.
  • Return on capital employed of 24.7%.
  • Quarterly profit up 33.7% on a year ago.
  • Quarterly sales up 24.3% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides its products under Orofer-Xt, Zostum, Bevon, Amaryl M,…

Headquarters
Pune
Employees
6,914
Sector
Healthcare
ISIN
INE168P01015
Website
emcure.com

Price range

52 weeks

₹1,312.30₹2,266.40

Today

₹2,181.10₹2,253.20
Avg volume (3M)
1.9 L
1-year return
plus 69.5%
From 52-week high
minus 2.4%

Analyst consensus

8 analysts
Strong buyMean target ₹2,422.50 plus 9.5%

Target range, with today’s price

Low ₹2,150.00High ₹2,751.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
EMCUREEmcure Pharmaceuticals2,212.80minus 1.43%41,97938.47.8624.7%21.4%19.8%15.4%20.2%0.16%plus 69.5%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
2,2702,3632,4702,5802,820
1,8311,9031,9842,0722,246
439460485508575
19.3%19.5%19.7%19.7%20.4%
39.534.540.92516.3
32.53846.431.535.6
105105106110110
–−38.2−32.61.6–
341314341394446
26.4%26.3%28.6%25.7%27.1%
243231243294326
12.8512.1612.8415.5017.14

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+15.4%
Profit CAGR 3Y
+20.2%
EPS CAGR 3Y
+18.3%
ROE
21.4%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
5,9316,5827,8089,116
–+11.0%+18.6%+16.7%
4,7305,3526,3397,327
1,2011,2301,4691,789
20.2%18.7%18.8%19.6%
−4.910.8−1.2111
163201140123
260312384415
−25.6−0.227.9−74.4
7477279711,287
24.8%27.5%27.2%26.9%
532498681924
–minus 6.4%+36.8%+35.7%
29.4327.5736.4348.77

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
181181189190
2,3202,7714,2574,760
2,3342,3351,0231,521
1,8372,5192,7643,141
6,6737,8068,2339,612
2,2312,4112,4442,576
420146141257
55.818.72121.7
261398198103
3,7064,8325,4296,654
6,6737,8068,2339,612

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
7471,097852944
−468−713−94−1,193
−145−164−814343
134221−56.393.9
−403−307−407−548
343790445396
−36.2−54.3–−56.9

Shareholding pattern

Source: NSE filings
77.8%
promoters
  • Promoters77.82%
  • Public22.18%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202677.82%22.18%minus 0.01
30 Jun 202677.83%22.17%minus 0.04
31 Mar 202677.87%22.13%0.00
31 Dec 202577.87%22.13%minus 0.01
30 Sep 202577.88%22.12%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you